54582-34-2

Basic information

• Product Name: N-(4-METHYLBENZYL)UREA
• Synonyms: N-(4-METHYLBENZYL)UREA
• CAS NO: 54582-34-2
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.2
• Mol File: 54582-34-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 198-199°
• Boiling Point: 299.8°C at 760 mmHg
• Flash Point: 135.1°C
• Appearance: /
• Density: 1.108g/cm³
• Vapor Pressure: 0.00116mmHg at 25°C
• Refractive Index: 1.558
• CAS DataBase Reference: N-(4-METHYLBENZYL)UREA(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-METHYLBENZYL)UREA(54582-34-2)
• EPA Substance Registry System: N-(4-METHYLBENZYL)UREA(54582-34-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 54582-34-2(Hazardous Substances Data)

Usage

General Description

N-(4-methylbenzyl)urea is a chemical compound that consists of a urea molecule with a 4-methylbenzyl substituent. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. N-(4-METHYLBENZYL)UREA is a white crystalline solid that is sparingly soluble in water, but soluble in organic solvents. N-(4-methylbenzyl)urea has been investigated for its potential application as a corrosion inhibitor and as a ligand in coordination chemistry. It is considered to be relatively stable under normal conditions, but should be handled and stored in accordance with standard safety procedures for handling organic chemicals.

InChI:InChI=1/C9H12N2O/c1-7-2-4-8(5-3-7)6-11-9(10)12/h2-5H,6H2,1H3,(H3,10,11,12)

Upstream product

• 590-28-3 potassium cyanate 
• 104-84-7 para-methylbenzylamine 
• 26177-45-7 4-methylbenzylamine hydrochloride 
• 57-13-6 urea 
• 61642-86-2 S-phenyl thiocarbamate 
• 95062-72-9 S-(4-methylphenyl) thiocarbamate 
• 95062-74-1 S-(4-chlorophenyl) thiocarbamate 
• 95062-75-2 S-(4-bromophenyl) thiocarbamate 
• 589-18-4 4-Methylbenzyl alcohol 
• 98952-71-7 4-Methyl-benzylcyanamid 

Downstream Products

• 87096-66-0 N-nitroso-N-(p-methylbenzyl)urea 
• 105686-07-5 1-(4-methylbenzyl)imidazolidinetrione 
• 128043-62-9 ethyl 1-(4-methylbenzyl)-2,4,5-trioxoimidazolidine-3-acetate 
• 51884-04-9 N-carbamoyl-4-methylbenzamide 
• 1616092-08-0 C₂₀H₂₁N₃O₃S 
• 1616092-13-7 C₁₉H₁₇Cl₂N₃O₂S 
• 1616092-22-8 C₂₁H₂₅N₅O₃ 
• 1616092-26-2 C₂₀H₂₁Cl₂N₅O₂ 
• 1616091-64-5 (2-(5-(4-methylbenzyl)-1-(4-methoxybenzyl)-1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazin-2-ylamino)ethyl)guanidine 
• 1616091-69-0 (2-(1-(3,4-dichlorobenzyl)-5-(4-methylbenzyl)-1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazin-2-ylamino)ethyl)guanidine 
• 1616091-97-4 C₁₁H₁₁N₃O₂S 
• 1616092-03-5 C₁₂H₁₃N₃O₂S 
• 1616091-90-7 C₁₃H₁₇N₃O₃S 

Relevant articles and documents

Nano cerium oxide as a recyclable catalyst for the synthesis of N-monosubstituted ureas with the aid of acetaldoxime as an effective water surrogate

A new method for the synthesis of N-monosubstituted ureas has been developed by the reaction of cyanamides with acetaldoxime in the presence of nano cerium oxide as an efficient and recyclable catalyst.

Selective synthesis of secondary amines via N-alkylation of primary amines and ammonia with alcohols by supported copper hydroxide catalysts

The N-alkylation of primary amines and ammonia (in situ generated from urea or aqueous ammonia) with alcohols to secondary amines was efficiently promoted by supported copper hydroxide catalysts, Cu(OH)xAl2O 3 and Cu(OH)x/TiO2. The observed catalysis was truly heterogeneous, and the catalysts could be reused without an appreciable loss of catalytic performance.

Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5- trioxoimidazolidine-1-acetic acids

A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)IC50(AR) was > 1000 in some compounds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5- trioxoimidazolidine-1-acetic acid (NZ-314) was selected as the candidate for clinical development.